_negative-charge-and-poly-adp-ribosylation-a-scientific-animation.jpg "Negative Charge and Poly-ADP-Ribosylation: A Scientific Animation from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 1 min 12 sec
✓ Published: 07-Apr-2014
✓ Published: 07-Apr-2014
Description:
A short 2D animation describing how a molecule, PARP-1, binds to DNA during the DNA repair process.
A short 2D animation describing how a molecule, PARP-1, binds to DNA during the DNA repair process.
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_what-key-factors-impact-prostate-cancer-treatment-decisions.webp "Prostate cancer expert Dr. Channing Paller reviews key variables that impact prostate cancer treatment decisions and explains immunotherapy, PARP inhibitors, and personalized medicine.nnDr. Channing Paller is Director of Prostate Cancer Clinical Research at Johns Hopkins Medicine. Learn more about Dr. Paller here: https://www.hopkinsmedicine.org/profiles/details/channing-paller")
_2021-07-09-parp-i-for-non-hrd-population-dr-ryan-spencer-mp4.webp "2021-07-09 PARP-i for non-HRD population - Dr. Ryan Spencer.mp4 from parp")
_prostate-cancer-treatment-decisions-how-do-genetic-test-results-impact-your-options.webp "How do genetic test results impact prostate cancer treatment options? Dr. Nima Sharifi explains BRCA mutations, germline genes, and somatic mutations—and discusses when treatment with PARP inhibitors may be appropriate. Dr. Nima Sharifi is Director of the Genitourinary (GU) Malignancies Research Center at the Cleveland Clinic. Learn more here: https://www.lerner.ccf.org/cancerbio/sharifi/")
⏲ 2 min 54 sec ✓ 10-Dec-2020
_an-overview-of-metastatic-breast-cancer-treatment-options.webp "What metastatic breast cancer (MBC) treatment options are available? Dr. Jane Lowe Meisel provides an overview of MBC treatment approaches, including CDK4-6 inhibitors, tyrosine kinase inhibitors, PARP inhibitors, and immunotherapy.nnJane Lowe Meisel, MD is an Associate Professor of Hematology and Medical Oncology at Winship Cancer Institute at Emory University. Learn more about Dr. Meisel here: https://winshipcancer.emory.edu/bios/faculty/meisel-jane-l.html")
_wicked-fart.webp "Muesli maketh the man.")
_parp-serwis.webp "CreditsnCLIENT: PARPnAGENCY: Scholz & FriendsnPRODUCTION: Dorota SieradzkanANIMATION DIRECTOR: Michal Socha, BrosFXnCREATION: Agnieszka Niska- Wojcik, BrosFXnREALIZATION: BrosFX: Directing, Concept Design, Animation, Postproduction")
_e4-sting-2007.webp "My submission to the E4 stings competition 2007.")
_parp-inhibitor-monotherapy.webp "In this GU CONNECT programme, brought to you by Dr Neal Shore, you’ll follow a patient through their metastatic castration-resistant prostate cancer (mCRPC) journey and explore the clinical implementation of genetic testing and monotherapy treatment with a PARPi.nnWatch the 5-minute animated video and download the accompanying slides for an update on:nn- Efficacy and safety profiles of PARP inhibitors for prostate cancern- The role of genetic testing and how to use it to assess HRRm status and")
_what-key-factors-impact-prostate-cancer-treatment-decisions.jpg)
_2021-07-09-parp-i-for-non-hrd-population-dr-ryan-spencer-mp4.jpg)
_prostate-cancer-treatment-decisions-how-do-genetic-test-results-impact-your-options.jpg)
_an-overview-of-metastatic-breast-cancer-treatment-options.jpg)
_wicked-fart.jpg)
_parp-serwis.jpg)
_e4-sting-2007.jpg)
_parp-inhibitor-monotherapy.jpg)
![[+]](/images/menu.gif){kind=small}